Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice

Orzetti, Sabrina; Tommasi, Federica; Bertola, Antonella; Bortolin, Giorgia; Caccin, Elisabetta; Cecco, Sara; Ferrarin, Emanuela; Giacomin, Elisa; Baldo, Paolo

doi:10.3390/ijms23063012

Cited by 7 publications

(4 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os dois principais tipos de terapia-alvo são os anticorpos monoclonais e os inibidores de moléculas pequenas (Orzetti et al, 2022). Várias moléculas são o foco de ensaios clínicos para terapia-alvo no glioblastoma.…”

Section: Terapia-alvounclassified

Terapias-alvo no tratamento do glioblastoma em adultos: Uma revisão de escopo

Ramos,

Matsuda,

Czepula

2024

RSD

View full text Add to dashboard Cite

Dentro do espectro das neoplasias primárias do sistema nervoso central, o glioblastoma é o subtipo mais prevalente, agressivo e letal, apesar das intervenções terapêuticas. Nesse cenário, a terapia-alvo, ao desenvolver medicamentos direcionados a moléculas específicas do processo carcinogênico, surge como uma opção verdadeiramente revolucionária. Portanto, esta revisão tem como objetivo mapear na literatura as terapias-alvo que são ou podem ser usadas no tratamento do glioblastoma em adultos visando a regressão do câncer. Este é um estudo metodológico de revisão de escopo. As bases de dados utilizadas foram: BVS, Pubmed, Embase, Scopus e BDTD. No total, foram identificados 637 estudos, dos quais 31 foram selecionados conforme critérios de inclusão; além disso, 4 artigos foram incluídos manualmente. Mediante a leitura, alguns fármacos, como o apatinibe, osimertinibe e cetuximabe, mostraram-se efetivos nos estudos realizados, contudo, carecem de aplicações em ensaios clínicos maiores para embasar sua incorporação nos esquemas de terapia padrão. O bevacizumabe já é consolidado no tratamento de glioblastoma recorrente e/ou terapia de segunda ou terceira linhas. Por fim, concluiu-se que embora o tratamento e prognóstico do paciente com glioblastoma ainda permaneça obscuro atualmente, acredita-se e tem-se esperança de que em um futuro promissor a terapia molecular direcionada servirá como aliada no tratamento curativo para esse câncer, visto que já há evidências de alguns melhorarem a qualidade de vida com alívio de sintomas, aumentarem o tempo livre de progressão da doença e/ou a sobrevida do paciente ainda que por determinado tempo.

show abstract

Section: Terapia-alvounclassified

Terapias-alvo no tratamento do glioblastoma em adultos: Uma revisão de escopo

Ramos,

Matsuda,

Czepula

2024

RSD

View full text Add to dashboard Cite

show abstract

“…Conventional therapeutic approaches involving surgery, radiation therapy and chemotherapy have major drawbacks and many patients with metastatic or recurrent disease still face dismal outcomes [ 2 , 3 ]. In the last decade, various targeted treatments have considerably evolved owing to increasing knowledge in cancer molecular medicine and in immuno-oncology, allowing the development of precision medicine as a more specific and less toxic way to manage cancer [ 4 ]. Antitumor immunotherapy provided a major advance in the treatment of cancer by modulating the immune system to enhance its ability to recognize and destroy the malignant cells [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

et al. 2023

View full text Add to dashboard Cite

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressing a surface receptor, called CAR, that specifically targets antigens expressed on the surface of tumor cells. In hematological malignancies like leukemias, myeloma, and non-Hodgkin B-cell lymphomas, adoptive CAR-T cell therapy has shown efficacy in treating chemotherapy refractory patients. However, the value of this therapy remains inconclusive in the context of solid tumors and is restrained by several obstacles including limited tumor trafficking and infiltration, the presence of an immunosuppressive tumor microenvironment, as well as adverse events associated with such therapy. Recently, CAR-Natural Killer (CAR-NK) and CAR-macrophages (CAR-M) were introduced as a complement/alternative to CAR-T cell therapy for solid tumors. CAR-NK cells could be a favorable substitute for CAR-T cells since they do not require HLA compatibility and have limited toxicity. Additionally, CAR-NK cells might be generated in large scale from several sources which would suggest them as promising off-the-shelf product. CAR-M immunotherapy with its capabilities of phagocytosis, tumor-antigen presentation, and broad tumor infiltration, is currently being investigated. Here, we discuss the emerging role of CAR-T, CAR-NK, and CAR-M cells in solid tumors. We also highlight the advantages and drawbacks of CAR-NK and CAR-M cells compared to CAR-T cells. Finally, we suggest prospective solutions such as potential combination therapies to enhance the efficacy of CAR-cells immunotherapy.

show abstract

“…Despite enormous progress in the diagnosis and treatment of cancer in recent decades, cancer is still difficult to cure. New methods used in cancer treatment include immuno-oncology, gene therapy, molecular targeted (personalized) therapy, and the photodynamic techniques [ 1 , 2 , 3 ]. The contemporary strategy for combating these dangerous diseases is based primarily on developing diagnostic methods, designing modern drugs and ways of precisely delivering them to the affected places.…”

Section: Introductionmentioning

confidence: 99%

Chitosan Composites Containing Boron-Dipyrromethene Derivatives for Biomedical Applications

Smolarkiewicz-Wyczachowski

Kaczmarek

Piskorz

et al. 2023

IJMS

View full text Add to dashboard Cite

The work is devoted to preparing and characterizing the properties of photosensitive composites, based on chitosan proposed for photodynamic therapy. Chitosan films with a 5% addition of two BODIPY dyes were prepared by solution casting. These dyes are dipyrromethene boron derivatives with N-alkyl phthalimide substituent, differing in the presence of iodine atoms in positions 2 and 6 of the BODIPY core. The spectral properties of the obtained materials have been studied by infrared and UV-vis absorption spectroscopy and fluorescence, both in solutions and in a solid state. Surface properties were investigated using the contact angle measurement. The morphology of the sample has been characterized by Scanning Electron and Atomic Force Microscopy. Particular attention was paid to studying the protein absorption and kinetics of the dye release from the chitosan. Adding BODIPY to the chitosan matrix leads to a slight increase in hydrophilicity, higher structure heterogeneity, and roughness, than pure chitosan. The presence of iodine atoms in the BODIPY structure caused the bathochromic effect, but the emission quantum yield decreased in the composites. It has been found that BODIPY-doped chitosan interacts better with human serum albumin and acidic α-glycoprotein than unmodified chitosan. The release rate of dyes from films immersed in methanol depends on the iodine present in the structure.

show abstract

Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice

Cited by 7 publications

References 77 publications

Terapias-alvo no tratamento do glioblastoma em adultos: Uma revisão de escopo

Terapias-alvo no tratamento do glioblastoma em adultos: Uma revisão de escopo

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Chitosan Composites Containing Boron-Dipyrromethene Derivatives for Biomedical Applications

Contact Info

Product

Resources

About